ULTRAGENYX PHARMACEUTICAL INC (RARE) — insider trading
Health Care · NASDAQ
ULTRAGENYX PHARMACEUTICAL INC (RARE) has 42 reported SEC Form 4 insider transactions in our data, including 12 open-market sales among the most recent 42 (latest 2026-10-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Horn Howard | Officer (Chief Financial Officer) | Open-market sale | 7,066 | $15.27 | $107.9K | Form 4 |
| 2026-09-15 | Huizenga Theodore Alan | Officer (SVP, Chief Accounting Officer) | Open-market sale | 1,283 | $13.57 | $17.4K | Form 4 |
| 2026-09-03 | Huizenga Theodore Alan | Officer (SVP, Chief Accounting Officer) | Open-market sale | 161 | $13.99 | $2.3K | Form 4 |
| 2026-08-03 | Horn Howard | Officer (Chief Financial Officer) | Open-market sale | 4,696 | $24.92 | $117.0K | Form 4 |
| 2026-08-03 | Parschauer Karah Herdman | Officer (EVP and Chief Legal Officer) | Open-market sale | 1,900 | $24.92 | $47.3K | Form 4 |
| 2026-07-01 | Horn Howard | Officer (Chief Financial Officer) | Open-market sale | 4,698 | $33.13 | $155.6K | Form 4 |
| 2026-06-15 | Parschauer Karah Herdman | Officer (EVP and Chief Legal Officer) | Open-market sale | 1,899 | $24.62 | $46.8K | Form 4 |
| 2026-06-15 | Sanders Corazon (Corsee) D. | Director | Open-market sale | 2,000 | $25.05 | $50.1K | Form 4 |
| 2026-06-01 | Horn Howard | Officer (Chief Financial Officer) | Open-market sale | 4,653 | $23.77 | $110.6K | Form 4 |
| 2026-05-18 | SULIMAN SHEHNAAZ | Director | Open-market sale | 5,740 | $25.12 | $144.2K | Form 4 |
| 2026-05-14 | Dunsire Deborah | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | Dunsire Deborah | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-14 | WELCH DANIEL G | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | WELCH DANIEL G | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-14 | NARACHI MICHAEL | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | NARACHI MICHAEL | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-14 | Sanders Corazon (Corsee) D. | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | Sanders Corazon (Corsee) D. | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-14 | Ray Amrit | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | Ray Amrit | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-14 | SULIMAN SHEHNAAZ | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | SULIMAN SHEHNAAZ | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-14 | Fust Matthew K | Director | Grant / award / vesting (derivative) | 14,058 | — | $0 | Form 4 |
| 2026-05-14 | Fust Matthew K | Director | Grant / award / vesting | 7,751 | — | $0 | Form 4 |
| 2026-05-05 | Crombez Eric | Officer (EVP and Chief Medical Officer) | Open-market sale | 344 | $24.96 | $8.6K | Form 4 |
| 2026-05-01 | Horn Howard | Officer (Chief Financial Officer) | Open-market sale | 4,683 | $24.90 | $116.6K | Form 4 |
| 2026-04-22 | Huizenga Theodore Alan | Officer (SVP, Chief Accounting Officer) | Grant / award / vesting (derivative) | 7,348 | — | $0 | Form 4 |
| 2026-04-22 | Huizenga Theodore Alan | Officer (SVP, Chief Accounting Officer) | Grant / award / vesting | 20,241 | — | $0 | Form 4 |
| 2026-04-16 | Horn Howard | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 59,952 | — | $0 | Form 4 |
| 2026-04-16 | Horn Howard | Officer (Chief Financial Officer) | Grant / award / vesting | 34,674 | — | $0 | Form 4 |
| 2026-04-16 | Crombez Eric | Officer (EVP and Chief Medical Officer) | Grant / award / vesting (derivative) | 59,952 | — | $0 | Form 4 |
| 2026-04-16 | Crombez Eric | Officer (EVP and Chief Medical Officer) | Grant / award / vesting | 34,674 | — | $0 | Form 4 |
| 2026-04-16 | Harris Erik | Officer (EVP & Chief Commercial Officer) | Grant / award / vesting (derivative) | 49,960 | — | $0 | Form 4 |
| 2026-04-16 | Harris Erik | Officer (EVP & Chief Commercial Officer) | Grant / award / vesting | 28,895 | — | $0 | Form 4 |
| 2026-04-16 | Parschauer Karah Herdman | Officer (EVP and Chief Legal Officer) | Grant / award / vesting (derivative) | 49,960 | — | $0 | Form 4 |
| 2026-04-16 | Parschauer Karah Herdman | Officer (EVP and Chief Legal Officer) | Grant / award / vesting | 28,895 | — | $0 | Form 4 |
| 2026-04-16 | Pinion John Richard | Officer (See Remarks) | Grant / award / vesting (derivative) | 79,936 | — | $0 | Form 4 |
| 2026-04-16 | Pinion John Richard | Officer (See Remarks) | Grant / award / vesting | 23,116 | — | $0 | Form 4 |
| 2026-04-16 | Huang Dennis Karl | Officer (See Remarks) | Grant / award / vesting (derivative) | 79,936 | — | $0 | Form 4 |
| 2026-04-16 | Huang Dennis Karl | Officer (See Remarks) | Grant / award / vesting | 23,116 | — | $0 | Form 4 |
| 2026-04-16 | KAKKIS EMIL D | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 132,693 | — | $0 | Form 4 |
| 2026-04-16 | KAKKIS EMIL D | Director, Officer (President & CEO) | Grant / award / vesting | 76,745 | — | $0 | Form 4 |
Ask the chat about RARE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ULTRAGENYX PHARMACEUTICAL INC (RARE).
Last updated 2026-10-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.